Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
Status:
Recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
Dementia with Lewy Bodies (DLB) is an alphasynucleinopathy and the second most common form of
dementia in the elderly. DLB shares striking neuropathological and clinical similarities with
both Parkinson's disease (PD) and Alzheimer's disease (AD). Nilotinib (Tasigna®, AMN107,
Novartis, Switzerland) is approved by the FDA and is well tolerated for CML treatment at oral
doses of 600-800mg daily. The Investigators propose to perform a phase II randomized, double
blinded, placebo controlled study to evaluate the impact of Nilotinib in patients with DLB.